FDA Accelerates Review of Treatments for Serious Mental Illness Following Executive Order

FDA accelerates psilocybin and methylone mental health treatments following executive action. This decision could revolutionize psychiatric care while raising regulatory concerns. The move reflects growing acceptance of psychedelic therapies in medical practice.